2247026-22-6

Nedosiran sodium is a RNAi therapy for primary hyperoxaluria that selectively reduce hepatic expression of lactate dehydrogenase^[3].
Nedosiran sodium specially inhibits hepatic expression of lactate dehydrogenase (LDHA)^[3].
Nedosiran sodium is a double-strand siRNA molecule that is conjugated with GalNAc, which takes advantage of the aforementioned unique asialoglycoprotein receptor (ASGPR) delivery system in the liver. Nedosiran sodium is administered by monthly subcutaneous injection. Nedosiran sodium decreases plasma oxalate in animal models^[3].